eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies.

Active-site mTOR inhibitors (asTORi) hold great promise for targeting dysregulated mTOR signaling in cancer. Because of the multifaceted nature of mTORC1 signaling, identification of reliable biomarkers for the sensitivity of tumors to asTORi is imperative for their clinical implementation. Here, we show that cancer cells acquire resistance to asTORi by downregulating eukaryotic translation initiation factor (eIF4E)-binding proteins (4E-BPs-EIF4EBP1, EIF4EBP2). Loss of 4E-BPs or overexpression of eIF4E renders neoplastic growth and translation of tumor-promoting mRNAs refractory to mTOR inhibition. Conversely, moderate depletion of eIF4E augments the anti-neoplastic effects of asTORi. The anti-proliferative effect of asTORi in vitro and in vivo is therefore significantly influenced by perturbations in eIF4E/4E-BP stoichiometry, whereby an increase in the eIF4E/4E-BP ratio dramatically limits the sensitivity of cancer cells to asTORi. We propose that the eIF4E/4E-BP ratio, rather than their individual protein levels or solely their phosphorylation status, should be considered as a paramount predictive marker for forecasting the clinical therapeutic response to mTOR inhibitors.

[1]  N. Sonenberg,et al.  Translational homeostasis via the mRNA cap-binding protein, eIF4E. , 2012, Molecular cell.

[2]  Nicholas T. Ingolia,et al.  The translational landscape of mTOR signalling steers cancer initiation and metastasis , 2012, Nature.

[3]  Gordon B Mills,et al.  Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. , 2012, Cancer cell.

[4]  M. Hall,et al.  Rapamycin passes the torch: a new generation of mTOR inhibitors , 2011, Nature Reviews Drug Discovery.

[5]  N. Ilić,et al.  PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis , 2011, Proceedings of the National Academy of Sciences.

[6]  E. Jacinto,et al.  mTOR complex 2 signaling and functions , 2011, Cell cycle.

[7]  A. Zask,et al.  Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review , 2011, Expert opinion on therapeutic patents.

[8]  J. Blenis,et al.  The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. , 2011, Trends in biochemical sciences.

[9]  E. D. de Vries,et al.  Everolimus for advanced pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[10]  D. Sabatini,et al.  mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.

[11]  Q. She,et al.  4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. , 2010, Cancer cell.

[12]  N. Sonenberg,et al.  mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs , 2010, Science.

[13]  R. Jackson,et al.  The mechanism of eukaryotic translation initiation and principles of its regulation , 2010, Nature Reviews Molecular Cell Biology.

[14]  B. Pulendran,et al.  Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production , 2010, Proceedings of the National Academy of Sciences.

[15]  C. Chresta,et al.  Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) , 2009, The Biochemical journal.

[16]  D. Guertin,et al.  The Pharmacology of mTOR Inhibition , 2009, Science Signaling.

[17]  D. Sabatini,et al.  An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.

[18]  A. Hinnebusch,et al.  Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets , 2009, Cell.

[19]  Robbie Loewith,et al.  Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 , 2009, PLoS biology.

[20]  T. Hoang,et al.  Stability of Eukaryotic Translation Initiation Factor 4E mRNA Is Regulated by HuR, and This Activity Is Dysregulated in Cancer , 2008, Molecular and Cellular Biology.

[21]  B. Manning,et al.  Common corruption of the mTOR signaling network in human tumors , 2008, Oncogene.

[22]  A. Gingras,et al.  Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. , 2008, RNA.

[23]  H. Aburatani,et al.  ATF4-mediated induction of 4E-BP1 contributes to pancreatic beta cell survival under endoplasmic reticulum stress. , 2008, Cell metabolism.

[24]  J. Graff,et al.  Targeting the eukaryotic translation initiation factor 4E for cancer therapy. , 2008, Cancer research.

[25]  N. Sonenberg,et al.  Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. , 2007, Cancer research.

[26]  Tao Wang,et al.  Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. , 2007, The Journal of clinical investigation.

[27]  N. Sonenberg,et al.  Epigenetic Activation of a Subset of mRNAs by eIF4E Explains Its Effects on Cell Proliferation , 2007, PloS one.

[28]  J. Baselga,et al.  4E-Binding Protein 1, A Cell Signaling Hallmark in Breast Cancer that Correlates with Pathologic Grade and Prognosis , 2007, Clinical Cancer Research.

[29]  Johan Auwerx,et al.  Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity , 2004, Nature.

[30]  N. Sonenberg,et al.  Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. , 2004, Cancer cell.

[31]  P. Pandolfi,et al.  The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis , 2004, Nature Medicine.

[32]  C. Meschonat,et al.  Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor. , 1999, The Journal of surgical research.

[33]  S. Gygi,et al.  Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. , 1999, Genes & development.

[34]  A. Gingras,et al.  4E-BP3, a New Member of the Eukaryotic Initiation Factor 4E-binding Protein Family* , 1998, The Journal of Biological Chemistry.

[35]  A. Gingras,et al.  4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. , 1998, Genes & development.

[36]  A. Gingras,et al.  Structure of translation factor elF4E bound to m7GDP and interaction with 4E-binding protein , 1997, Nature Structural Biology.

[37]  Christine C. Hudson,et al.  Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. , 1997, Science.

[38]  A. Gingras,et al.  Cocrystal Structure of the Messenger RNA 5′ Cap-Binding Protein (eIF4E) Bound to 7-methyl-GDP , 1997, Cell.

[39]  A. Gingras,et al.  The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. , 1996, Oncogene.

[40]  M. Polymenis,et al.  An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc , 1996, Molecular and cellular biology.

[41]  N. Sonenberg,et al.  The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF-4 gamma and the translational repressors 4E-binding proteins , 1995, Molecular and cellular biology.

[42]  A. Gingras,et al.  Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function , 1994, Nature.

[43]  N. Sonenberg,et al.  Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap , 1990, Nature.

[44]  J. Stockman,et al.  Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2012 .

[45]  A. Rich,et al.  A multiple ribosomal structure in protein synthesis. , 1963, Proceedings of the National Academy of Sciences of the United States of America.